GEMCITABINE ACTAVIS 200 MG/VIAL

Country: Ísrael

Tungumál: enska

Heimild: Ministry of Health

Virkt innihaldsefni:

GEMCITABINE 200 MG/VIAL

Fáanlegur frá:

DEVRIES & CO. LTD

ATC númer:

L01BC05

Lyfjaform:

POWDER FOR SOLUTION FOR INFUSION

Stjórnsýsluleið:

I.V

Framleitt af:

ACTAVIS GROUP PTC ehf, ICELAND

Meðferðarhópur:

GEMCITABINE

Ábendingar:

Gemcitabine is indicated for the treatment of locally advanced or metastatic bladder cancer in combination with cisplatin. Gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas.Gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Gemcitabine monotherapy can be considered in elderly patients or those with performance status 2. Gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelial ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first-line therapy. Gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherap

Leyfisdagur:

2013-06-01